Discover Mapi's articles published in 2017

Thirty articles published (including one book chapter).

In many therapeutic areas such as Cardiovascular Diseases, Infectious Diseases, Neurological Disorders, Oncology, Psychiatry, Rare Diseases, and Rheumatology.

  1. Igarashi A, Tang W, Guerra I, Marié L, Cure S, Lopresti M. Cost-utility analysis of ledipasvir/ sofosbuvir for the treatment of genotype 1 chronic hepatitis C in Japan. Curr Med Res Opin. 2017; 33(1):11-21. https://www.ncbi.nlm.nih.gov/pubmed/27609424
  2. Igarashi A, Tang W, Cure S, Guerra I, Marié L, Lopresti M, et al. Cost-utility analysis of sofosbuvir for the treatment of genotype 2 chronic hepatitis C in Japan. Curr Med Res Opin. 2017; 33(1):1-10. https://www.ncbi.nlm.nih.gov/pubmed/27608157
  3. Stahmeyer JT, Rossol S, Liersch S, Guerra I, Krauth C. Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany. PLoS One. 2017; 12(1):e0169401. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5207688/
  4. Alemao E, Cawston H, Bourhis F, Al M, Rutten-van Molken M, Liao KP, et al. Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2017 Jan 12. pii: kew440. doi: 10.1093/rheumatology/kew440. [Epub ahead of print]. https://www.ncbi.nlm.nih.gov/pubmed/28087832
  5. Arnould B. Using patient-reported outcomes as tools for clinical practice: a new paradigm. In: Luscombe DK, Stonier PD, eds. Clinical Research Manual. Passfield, England: Euromed Communications; 2017:21.1-21.10.
  6. Svedbom A, Dalén J, Black CM, Kachroo S. Persistence and costs with subcutaneous TNF-alpha inhibitors in immune-mediated rheumatic disease stratified by treatment line. Patient Prefer Adherence. 2017; 11:95-106. https://www.ncbi.nlm.nih.gov/pubmed/28144130
  7. Burnett H, Earley A, Voors AA, Senni M, McMurray JJ, Deschaseaux C, et al. Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction: A Network Meta-Analysis. Circ Heart Fail. 2017; 10(1). pii: e003529. https://www.ncbi.nlm.nih.gov/pubmed/28087688
  8. Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J; the MSCOI Study Group and the European Multiple Sclerosis Platform. New insights into the burden and costs of multiple sclerosis in Europe. Multiple Sclerosis Journal. 2017;1-14. http://journals.sagepub.com/doi/pdf/10.1177/1352458517694432
  9. Long JA, Poinas G, Fiard G, Leprêtre M, Delaitre-Bonnin C, Rébillard X, Descotes JL. [Robot assisted radical prostatectomy: What are the evidences at the time of a specific funding?] Prog Urol. 2017 Feb 3. pii: S1166-7087(16)30782-5. [Epub ahead of print] [Article in French]. https://www.ncbi.nlm.nih.gov/pubmed/28169123
  10. Brengard-Bresler T, De Runz A, Bourhis F, Mezzine H, Khairallah G, Younes M, et al. [Postoperative quality of life of patients with a bacterial necrotizing dermis-hypodermitis or necrotizing fasciitis, a ten-year study]. Ann Chir Plast Esthet. 2017; 62(1):31-44. [Article in French]. https://www.ncbi.nlm.nih.gov/pubmed/26946930
  11. Largeron N, Petry KU, Jacob J, Bianic F, Anger D, Uhart M. An estimate of the public health impact and cost-effectiveness of universal vaccination with a 9-valent HPV vaccine in Germany. Expert Rev Pharmacoecon Outcomes Res. 2017; 17(1):85-98. https://www.ncbi.nlm.nih.gov/pubmed/27366939
  12. Arnould B, Gilet H, Patrick DL, Acquadro C. Item Reduction, Scoring, and First Validation of the ACCEPTance by the Patients of their Treatment (ACCEPT©) Questionnaire. Patient. 2017; 10(1):81-92. https://www.ncbi.nlm.nih.gov/pubmed/27456210
  13. Maiese BA, Pham AT, Shah MV, Eaddy MT, Lunacsek OE, Wan GJ. Hospitalization Costs for Patients Undergoing Orthopedic Surgery Treated With Intravenous Acetaminophen (IV-APAP) Plus Other IV Analgesics or IV Opioid Monotherapy for Postoperative Pain. Adv Ther. 2017;34(2):421-35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331089/
  14. Kerr C, Bottomley C, Shingler S, Giangregorio L, de Freitas HM, Patel C, et al. The importance of physical function to people with osteoporosis. Osteoporos Int. 2017 Mar 6. [Epub ahead of print]. https://www.ncbi.nlm.nih.gov/pubmed/28265717
  15. Bergrath E, Gerber RA, Gruben D, Lukic T, Makin C, Wallenstein G. Tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients who have had an inadequate response to nonbiologic DMARDs: systematic literature review and network meta-analysis. Int J Rheumatol. 2017;2017:8417249. https://www.hindawi.com/journals/ijr/2017/8417249/
  16. Huisman E, Papadimitropoulou K, Jarrett J, Bending M, Firth Z, Allen F, et al. Systematic literature review and network meta-analysis in highly active relapsing–remitting multiple sclerosis and rapidly evolving severe multiple sclerosis. BMJ Open 2017;7(3):e013430. http://bmjopen.bmj.com/content/7/3/e013430.long
  17. Leleu X, Kyriakou C, Vande Broek I, Murphy P, Bacon P, Lewis P, et al. Prospective longitudinal study on quality of life in relapse/refractory multiple myeloma patients receiving second or third line lenalidomide or bortezomib treatment. Blood Cancer J. 2017;17;7(3):e543. https://www.ncbi.nlm.nih.gov/pubmed/28304402
  18. Jurecki E, Cunningham A, Birardi V, Gagol G, Acquadro C. Development of the US English Version of the Phenylketonuria – Quality of Life (PKU-QOL) Questionnaire. Health Qual Life Outcomes. 2017;15(1):46 2017. https://www.ncbi.nlm.nih.gov/pubmed/28274259
  19. Cawston H, Bourhis F, Eriksson J, Ruffo P, D'Agostino P, Turini M, et al. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context. 2017;6:212298. https://www.ncbi.nlm.nih.gov/pubmed/28392826
  20. Carcao M, Kearney S, Santagostino E, Oyesiku JOO, Young NL, Meunier J, et al. Insight into health-related quality of life of young children with haemophilia B treated with long-acting nonacog beta pegol recombinant factor IX. Haemophilia. 2017 Mar 30. [Epub ahead of print]. https://www.ncbi.nlm.nih.gov/pubmed/28371032
  21. Benmedjahed K, Wang YG, Lambert J, Evans C, Hwang S, Black J, et al. MW. Assessing sleepiness and cataplexy in children and adolescents with narcolepsy: a review of current patient-reported outcomes. Sleep Medicine. 2017; 32:143-9. http://www.sleep-journal.com/article/S1389-9457(17)30012-6/pdf
  22. Papadimitropoulou K, Vossen C, Karabis A, Donatti C, Kubitz N. Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis. Curr Med Res Opin. 2017;33(4):701-11. https://www.ncbi.nlm.nih.gov/pubmed/28035869
  23. Svedbom A, Storck C, Kachroo S, Govoni M, Khalifa A. Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. Patient Prefer Adherence. 2017 Apr 7;11:719-29. https://www.ncbi.nlm.nih.gov/pubmed/28435230
  24. Cooper WA, Russell PA, Cherian M, Duhig EE, Godbolt D, Jessup PJ, et al. Intra- and Inter-Observer Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer (NSCLC). Clin Cancer Res. 2017 Apr 18. pii: clincanres.0151.2017. doi: 10.1158/1078-0432.CCR-17-0151. [Epub ahead of print]. https://www.ncbi.nlm.nih.gov/pubmed/28420726
  25. Young AH, Evitt L, Brignone M, Diamand F, Atsou K, Campbell R, et al. Cost-utility evaluation of vortioxetine in patients with Major Depressive Disorder experiencing inadequate response to alternative antidepressants in the United Kingdom. J Affect Disord. 2017 Apr 17;218:291-8. https://www.ncbi.nlm.nih.gov/pubmed/28478358
  26. Kauf TL, Prabhu VS, Medic G, Borse RH, Miller B, Gaultney J, et al. Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections. BMC Infect Dis. 2017;17(1):314. https://www.ncbi.nlm.nih.gov/pubmed/28454524
  27. McArthur GA, Mohr P, Ascierto PA, Arance A, Banos Hernaez A, Kaskel P, et al. Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study). Oncologist. 2017 May 19. pii: theoncologist.2016-0272. doi: 10.1634/theoncologist.2016-0272. [Epub ahead of print]. https://www.ncbi.nlm.nih.gov/pubmed/28526721
  28. Prabhu V, Foo J, Ahir H, Sarpong E, Merchant S. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK. J Med Econ. 2017 May 22:1-20. [Epub ahead of print]. https://www.ncbi.nlm.nih.gov/pubmed/28532194
  29. Weijers L, Baerwald C, Mennini FS, Rodríguez-Heredia JM, Bergman MJ, Choquette D, et al. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada. Rheumatol Int. 2017 May 30. doi: 10.1007/s00296-017-3739-9. [Epub ahead of print]. https://www.ncbi.nlm.nih.gov/pubmed/28560470
  30. Zanotti G, Hunger M, Perkins JJ, Horblyuk R, Martin M. Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States. BMC Cancer. 2017 Jun 2;17(1):393. https://www.ncbi.nlm.nih.gov/pubmed/28578656